ACCESS ALL ASIA: Speedier approvals available soon in China - for a fee
This article was originally published in Clinica
With China in the midst of rolling out a raft of new medtech regulations, medtech manufacturers have to go through more hoops to get their product approved. Now, companies also have to contend with forking out a substantial sum to the China Food and Drug Administration in registration fees.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.